OSSFILA Technology Limited is a Hong Kong-based startup company specialized in the R&D and manufacture of novel 3D printing material and 3D printed bone implants. Founded by three affiliates from the University of Hong Kong in 2018, OSSFILA aims to resolve the supply shortage of donor bone implants. The 3D-printing product composition will be based on a novel copolymer which promote superior biocompatibility while maintaining similar mechanical strength and durability of a normal bone compared to current alternatives. OSSFILA 3D-printing material and 3D-printed bone implants will offer a safe, effective and patient-specific solution for patients in need.
Our team consists of experienced scientists with post-graduate degrees specialized in biomaterials, medical engineering and clinical developments. We also have strong industrial and university collaborations to leverage our expertise to bring innovations and facilitate researchers and physicians in the orthopaedics field.
OSSFILA’s core product is a 3D-printer filament mainly made up by PMMA and a novel copolymer which is a biocompatible material suitable to replace or integrate with natural bone. During bone surgery for various bone diseases, it is very common to replace natural bone with implants. These implants are usually made in standardized size by metal alloy which is expensive and cannot be integrate with natural bone. OSSFILA filament has been developed to solve this problem by providing the advantages of cost-effective, biocompatible, osteoconductive and patient-specific.
In the near future, we are going to develop different types of filament to suit different purpose and markets. In addition, we will develop the 3D-printing technology to optimize the use of OSSFILA filament as an orthopaedic implant and produce patient-specific 3D-printed implant. Any business or research collaboration are always welcome.